Fig. 7.

EVs-miR-182-5p exerts promoting effect on tumorigenesis and metastasis of breast cancer cells in vivo by the CMTM7/EGFR/AKT axis. Mice were treated with EVs + inhibitor NC, EVs + miR-182-5p inhibitor, or EVs + miR-182-5p inhibitor + si-CMTM7. A Tumor volume of nude mice, the statistical power was 1; B Tumor weight of nude mice after 28 days of modeling, the statistical power was 1; C Expression of miR-182-5p in tumor tissues of nude mice detected by RT-qPCR, the statistical power was 1; D Expression of CMTM7, p-EGFR, EGFR, VEGF, p-AKT and AKT protein in tumor tissues of nude mice detected by Western blot analysis, the statistical power was 1; E–F Number E and size (F) of pulmonary metastasis in nude mice, the statistical power was 1; G–H CD31 (G) and Ki-67 (H) immunohistochemical staining of pulmonary metastasis tissues in nude mice, the statistical power was 1. N = 10 for mice following each treatment. ****p < 0.0001 compared with mice treated with EVs + inhibitor NC. ####p < 0.0001 compared with HUVECs treated with EVs + miR-182-5p inhibitor + si-NC. The experiment was conducted three times independently